Bursa City Hospital Pulmonary Medicine, Bursa, Turkey.
Bursa City Hospital Medical Biochemistry, Bursa, Turkey.
Medicine (Baltimore). 2023 Oct 20;102(42):e35588. doi: 10.1097/MD.0000000000035588.
Severe acute respiratory syndrome-coronavirus 2 and its variants are still a concern for the World. The effectiveness of the BioNTech and Sinovac vaccines against the B.1.617.2 variant, particularly in the intensive care unit, has been unclear. This study aimed to investigate the vaccine effectiveness of BioNTech and Sinovac vaccines in reducing severe disease, intubation, and mortality rates in B.1.617.2 infected patients followed in the intensive care unit. The data of 208 unvaccinated and 234 vaccinated B.1.617.2 variants were retrospectively reviewed. Severe disease status, complaints, the percent oxygen saturation in the blood at the first admission, and other clinical information during follow-up were recorded. With the BioNTech and Sinovac vaccines being the most common in the region, mortality rate, severe disease, and intubation were more frequent in the unvaccinated group. As for survival rates, 58.5 (137) of the vaccinated and 35.1 % (73) of the unvaccinated survived. In the vaccinated group, 64.3 % (27) of vaccinated with 3 Sinovac, 80 % (16) of 2 Sinovac and 1 BioNTech, and 71.7 % of 2 BioNTech survived. Vaccination with 2 doses of BioNTech and 3 doses of Sinovac reduces mortality. Furthermore, 2 doses of Sinovac and 1 dose of BioNTech are more protective.
严重急性呼吸综合征冠状病毒 2 及其变体仍然是全世界关注的焦点。BioNTech 和科兴疫苗对 B.1.617.2 变体的有效性，尤其是在重症监护病房，尚不清楚。本研究旨在调查 BioNTech 和科兴疫苗在降低重症监护病房 B.1.617.2 感染患者严重疾病、插管和死亡率方面的疫苗效力。回顾性分析了 208 名未接种疫苗和 234 名接种 B.1.617.2 变异体的患者的数据。记录了严重疾病状态、症状、首次入院时的血氧饱和度百分比以及随访期间的其他临床信息。由于 BioNTech 和科兴疫苗在该地区最为常见，未接种疫苗组的死亡率、严重疾病和插管更为频繁。就生存率而言，接种疫苗组有 58.5%（137 人）存活，未接种疫苗组有 35.1%（73 人）存活。在接种疫苗组中，3 剂科兴疫苗接种者中有 64.3%（27 人）、2 剂科兴疫苗加 1 剂 BioNTech 疫苗接种者中有 80%（16 人）、2 剂 BioNTech 疫苗接种者中有 71.7%（17 人）存活。接种 2 剂 BioNTech 和 3 剂科兴可降低死亡率。此外，2 剂科兴和 1 剂 BioNTech 的保护效果更好。
